4. Retinopathy
• Primary prevention group (Intensive vs. conventional)
– 23 vs 91 pts developed retinopathy in 6 years followup (Mean risk
reduction 76%)
• Secondary prevention group (Intensive vs. conventional)
– 77 vs 143 pts developed progressive retinopathy (Mean risk reduction
54%)
– 47% reduction of severe retinopathy, 56% reduction in laser
photocoagulation
• Transient worsening of retinopathy (22% vs. 13%) 18 months
5. Nephropathy
• Primary prevention group
– Mean risk reduction for microalbuminuria by 34% (p 0.04) intensive gp
• Secondary prevention group
– Mean risk reduction for microalbuminuria by 43% (p 0.001) intensive gp
• Risk reduction in albuminuria (54%) and microalbunimuria
(39%) in intensive treatment arms
6. Neuropathy
• Primary Prevention group
– 3% vs 10% developed neuropathy (69% reduction of neuropathy by 5
years, p0.006)
• Secondary Prevention group
– 7% vs 16% developed neuropathy (57% reduction of neuropathy by 5
years)
7. Secondary analysis
•
•
•
•
•
•
•
Severe hypoglycemic episodes 62 vs. 19/100 pt yrs
Hypoglycemia Coma / seizure episodes 16 vs. 5/100 pt yrs
Hospitalisation 54/40 pts vs. 36/27 pts
Major accidents 20 vs. 22 (2 fatalities, 1 vs. 1)
No difference in neuropsycholgical function
No death, MI or stroke
Wt gain ( overweight 12.7 vs. 9.3 /100 pt yrs)